checkAd

     105  0 Kommentare Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar - Seite 2

    • Dr. Tansey presented new analysis of combined interim data from two Phase 2 trials at the 1.6 mg/kg/day and 3.2 mg/kg/day doses, including 15 subjects from the OraGrowtH212 Trial and 20 subjects from the OraGrowtH210 Trial
    • Results of the analysis of the additional OraGrowtH212 subjects combined with OraGrowtH210 subjects continue to demonstrate that there is a durable response to LUM-201 from 6 to 12 months
    • Pre-treatment baseline AHV data, which was not captured for all of the subjects in our database, was available for 31 of the 35 subjects and showed that LUM-201 at both the 1.6 mg/kg/day and 3.2 mg/kg/day produced clinically meaningful increase in AHV from baseline
    • No treatment related Serious Adverse Events (SAEs), no discontinuation due to AEs, and no meaningful safety signals observed

    KOL Biographies

    Fernando Cassorla, M.D. is currently Chief of Pediatric Endocrinology at the Institute of Maternal and Child Research of the University of Chile, a position he has held since 1993. Previously, beginning in 1979 Dr. Cassorla served as Senior Investigator at the Developmental Endocrinology Branch of the National Institute of Child Health and Human Development, rising to the position of Clinical Director of this Institute in 1990. He has authored numerous chapters in pediatric endocrinology, authored or co-authored over 200 original articles in peer reviewed journals, and has presented over 300 abstracts at scientific meetings. Dr. Cassorla received his MD from the University of Chile. He is Board Certified in both Pediatrics and Pediatric Endocrinology, having completed his pediatric residency at the Albany Medical Center in New York and his fellowship in Pediatric Endocrinology at the Children´s Hospital of Philadelphia. Dr. Cassorla has received several international awards for his work and was elected to the Chilean Academy of Medicine for a lifetime position in 2003.

    Michael Tansey, M.D. is currently Clinical Professor, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, University of Iowa, Iowa City, Iowa, a position he has held since 2012, having first served as Clinical Assistant Professor there 2001-2006, then as Clinical Associate Professor 2006-2012. Dr. Tansey also currently serves as Clinical Director for Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Iowa. He has been a co-investigator for one of the 5 clinical centers for the NIH funded Diabetes Research in Children Network “DirecNet” group since 2001 and has co-authored numerous peer-reviewed scientific publications on brain function and growth in children with Type 1 diabetes. Dr. Tansey received his MD from Loyola Stritch School of Medicine, Maywood, Illinois, and completed his residency in pediatrics and his fellowship in pediatric endocrinology at the University of Iowa Children’s Hospital and University of Iowa Hospitals and Clinics, respectively. He has received several awards including the Riesz Award, University of Iowa, and the Mary Tyler Moore and S. Robert Levine, MD, Excellence in Clinical Research Award.

    Seite 2 von 3




    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar - Seite 2 Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) - Lumos Pharma, Inc. (NASDAQ:LUMO), a …